Yeah but you also said most larger biotech stocks are overpriced. And I do not agree with that statement.
The avg daily volume is almost triple what it was about 18 months ago. There are more people watching it these days, but I don't look at that as a recipe for success. You got the summary from myself, Hopefully and Tswenor which lays it out more or less.
Another way of approaching it is to keep just a portion of your investment intact. If you put all of the pieces together you have a high risk/high reward situation here. It is worth keeping some money in the game I believe although it is a matter of your appetite for risk.
btw - I would agree w/ your prediction of lower vs. higher. Don't think 1 but perhaps $1.3-$1.5. 60/40 chance it drifts lower from here.
No, not a chance. For FDA approval I don't think you'll see it until probably around Q1 2017. That said, this investment is not about the approval - it's about the progress. If SNGX can execute on the P3 clinical trials and produce positive results this stock will rise. But time is of the essence. These companies burn cash and it is a race against running out of king dollar. So they need to produce results quickly (i.e. next 3-6 months) and if they do good things will happen. If not, then as a shareholder your slope will steepen and not in the right direction.
For a newcomer, you ask a good question. First, welcome aboard. You have several people on this board with a few years experience following SNGX including self. There's a lot to learn about this company - much of it not that good unfortunately. The good is the raw pipeline and the low market cap. The bad is the lack of execution. So to answer your question directly, yes there is promise but the better question is can they execute on the goal? Track record speaks for itself - 0 drugs approved or even close to approved to date. Could this be the year of change? Many hope so.
I see a weak dollar as good for stocks particularly with international presence. AAS conference going on and earnings on Fri, I see BIIB in the $450-460 area by week's end. Let's see who is closer.
I don't think they are overpriced at all. They trade at low PEGs because they are growing so rapidly. Sure, if their pipelines slow and growth slows we have another issue but right now their businesses are white hot. They are producing cures, treatments and vaccines that are literally changing the world.
It's all about results, specifically clinical trial results. I think you know a lot about biotech, and when it comes to dev stage biotech investing the most important thing in a company in my eyes is how they place the race game. You don't want to get caught up with a company that cannot deliver and issues SOs on an annual basis - even if something eventually hits its often too late for you as a retail investor to profit from it.
The low market cap is the ONLY thing that's kept me here in town as it makes the upside vs. risk more palatable for me. It still did not preclude me from dumping most of my position as I lost confidence in management. But I evaluated the overall situation (like you do) and decided a small piece of this pie is still worth holding onto for the time being.
I think they are but not sure. Anyone know when it may come?
It's not a safe haven, it's a great investment that carries volatility along with it. There is nothing overvalued about the big biotechs. I know that you know how to read fundamentals and for the big biotechs they are excellent. If you want to try to promote your bubble agenda get to it but it you should acknowledge that these companies are just killing it right now.
Protocol clearance is what they are supposed to do - it should be a given if they follow the rules and do their job. Most companies don't even announce this detail. But it did make for interesting reading as I reminded myself about the "what if" potential of the treatment.